-
Rigel Pharmaceuticals Inc. (RIGL $18.80)
- $18.80 Fwd P/E: 8.86X Cap: $344M
- View RIGL Profile
- View Questions on RIGL
Detailed Quote
Questions on this company?
Become a Member
Company Profile
{tplLang.businessdescription | toLang tLang}
{ profileData.description }
{tplLang.details | toLang tLang}
{tplLang.ceo | toLang tLang}
{profileData.profile.details.ceo}
{tplLang.employees | toLang tLang}
{profileData.profile.details.employees | numeraljs '0,0'}
{tplLang.issuetype | toLang tLang}
{profileData.profile.details.issuetype | asIssueType}
{tplLang.industryclassifications | toLang tLang}
{tplLang.sector | toLang tLang}
{profileData.profile.classification.sector}
{tplLang.industry | toLang tLang}
{profileData.profile.classification.industry}
{tplLang.toolname| toLang tLang}
There is no {tplLang.toolname| toLang tLang} currently available for
{data.symbolstring}.
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
-
Rigel Pharmaceuticals Inc. (RIGL $18.80)
- $18.80 Fwd P/E: 8.86X Cap: $344M
- View RIGL Profile
- View Questions on RIGL
Q: Hi,
Please explain why RIGL (US) is down today about 22% after it went up yesterday 100% (mid-day).
My exceptions for the stock were to go up & up after RIGL announce it's trial being conducted by Imperial College London to evaluate the efficacy of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of COVID-19 pneumonia
Thanks,
Morris
Please explain why RIGL (US) is down today about 22% after it went up yesterday 100% (mid-day).
My exceptions for the stock were to go up & up after RIGL announce it's trial being conducted by Imperial College London to evaluate the efficacy of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of COVID-19 pneumonia
Thanks,
Morris
Insiders
Share Information
SEC Filings
News and Media